These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6311370)

  • 1. Ultrafiltrability and chromatographic properties of pyrophosphate, 1-hydroxyethylidene-1,1-bisphosphonate, and dichloromethylenebisphosphonate in aqueous buffers and in human plasma.
    Wiedmer WH; Zbinden AM; Trechsel U; Fleisch H
    Calcif Tissue Int; 1983 Jul; 35(4-5):397-400. PubMed ID: 6311370
    [No Abstract]   [Full Text] [Related]  

  • 2. The subcellular distribution of [14C]dichloromethylenebisphosphonate and [14C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells.
    Felix R; Guenther HL; Fleisch H
    Calcif Tissue Int; 1984 Jan; 36(1):108-13. PubMed ID: 6322939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma protein binding of APD: role of calcium and transferrin.
    Daley-Yates PT; Cal JC; Cockshott A; Pongchaidecha M; Gilchrist K
    Chem Biol Interact; 1992 Jan; 81(1-2):79-89. PubMed ID: 1730149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pyrophosphate and diphosphonates on calcium transport in red cells.
    Felix R; Fleisch H
    Experientia; 1977 Aug; 33(8):1003-5. PubMed ID: 196891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of bisphosphonates on glycolysis in cultured calvaria cells and their homogenate.
    Felix R; Fleisch H
    Experientia; 1983 Nov; 39(11):1293-5. PubMed ID: 6227496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation of bisphosphonates into insoluble material in human blood in vitro.
    Kautiainen S; Luurila S; Ylitalo P; Ylitalo R
    Methods Find Exp Clin Pharmacol; 1998 May; 20(4):289-95. PubMed ID: 9658377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diphosphonates: history and mechanisms of action.
    Fleisch H
    Metab Bone Dis Relat Res; 1981; 3(4-5):279-87. PubMed ID: 6300612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate prodrugs.
    Vepsäläinen JJ
    Curr Med Chem; 2002 Jun; 9(12):1201-8. PubMed ID: 12052172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of (dichloromethylene) diphosphonate in physiological fluids by ion-exchange chromatography with phosphorus-selective detection.
    Chester TL; Lewis EC; Benedict JJ; Sunberg RJ; Tettenhorst WC
    J Chromatogr; 1981 Sep; 225(1):17-25. PubMed ID: 6457843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of theophylline in human serum determined by ultrafiltration and equilibrium dialysis.
    Brørs O; Sager G; Sandnes D; Jacobsen S
    Br J Clin Pharmacol; 1983 Apr; 15(4):393-7. PubMed ID: 6849773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The binding of urate to plasma proteins determined by four different techniques.
    Hardwell TR; Manley G; Braven J; Whittaker M
    Clin Chim Acta; 1983 Sep; 133(1):75-83. PubMed ID: 6354516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and extrarenal acid buffering capacity.
    Freudiger H; Bonjour JP
    Calcif Tissue Int; 1989 Jan; 44(1):3-10. PubMed ID: 2521807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein binding to monosodium urate monohydrate, calcium pyrophosphate dihydrate, and silicon dioxide crystals. I. Physical characteristics.
    Kozin F; McCarty DJ
    J Lab Clin Med; 1977 Jun; 89(6):1314-25. PubMed ID: 16976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.
    Lin JH; Chen IW; deLuna FA; Hichens M
    J Pharmacol Exp Ther; 1993 Nov; 267(2):670-5. PubMed ID: 8246140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methods of determination, physico-chemical properties and pharmacokinetic signifance of plasma protein binding of drugs].
    Krieglstein J
    Arzneimittelforschung; 1973 Nov; 23(11):1527-9. PubMed ID: 4801656
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of 1-hydroxyethylidene-1,1-bisphosphonate (HEBP) and dichloromethylidene-bisphosphonate (Cl2MBP) on the structure of the organic matrix of heterotopically induced bone tissue.
    Ostrowski K; Wojtowicz A; Dziedzic-Goclawska A; Rozycka M
    Histochemistry; 1988; 88(3-6):207-12. PubMed ID: 2966784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of bisphosphonate drugs in pharmaceutical dosage formulations by ion chromatography with indirect UV detection.
    Tsai EW; Chamberlin SD; Forsyth RJ; Bell C; Ip DP; Brooks MA
    J Pharm Biomed Anal; 1994 Aug; 12(8):983-91. PubMed ID: 7819384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombination of human red cell membrane protein fractions with homologous lipids.
    Barzilay M; Condrea E; Ben-David E; De Vries A
    Biochim Biophys Acta; 1973 Jul; 311(4):576-93. PubMed ID: 4729831
    [No Abstract]   [Full Text] [Related]  

  • 19. Ultrastructural effects of diphosphonates on dental enamel.
    Simmelink JW
    Adv Dent Res; 1987 Dec; 1(2):356-65. PubMed ID: 2973330
    [No Abstract]   [Full Text] [Related]  

  • 20. Determination of unbound drug concentration and protein-drug binding fraction in plasma.
    Liu Z; Li F; Huang Y
    Biomed Chromatogr; 1999 Jun; 13(4):262-6. PubMed ID: 10416057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.